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Abstract
Background: CD23 is a differentiation/activation antigen expressed by a variety of hematopoietic and epithelial cells. It can
also be detected in soluble forms in biological fluids. Initially known as the low-affinity receptor for immunoglobulin E
(FceRII), CD23 displays various other physiologic ligands such as CD21, CD11b/c, CD47-vitronectin, and mannose-containing
proteins. CD23 mediates numerous immune responses by enhancing IgE-specific antigen presentation, regulating IgE
synthesis, influencing cell differentiation and growth of both B- and T-cells. CD23-crosslinking promotes the secretion of
pro-inflammatory mediators from human monocytes/macrophages, eosinophils and epithelial cells. Increased CD23
expression is found in patients during allergic reactions and rheumatoid arthritis while its physiopathologic role in these
diseases remains to be clarified.
Methodology/Principal Findings: We previously generated heptapeptidic countrestructures of human CD23. Based on in
vitro studies on healthy and arthritic patients’ cells, we showed that CD23-specific peptide addition to human macrophages
greatly diminished the transcription of genes encoding inflammatory cytokines. This was also confirmed by significant
reduction of mediator levels in cell supernatants. We also show that CD23 peptide decreased IgE-mediated activation of
both human and rat CD23
+ macrophages. In vivo studies in rat model of arthritis showed that CD23-blocking peptide
ameliorates clinical scores and prevent bone destruction in a dose dependent manner. Ex-vivo analysis of rat macrophages
further confirmed the inhibitory effect of peptides on their activation. Taken together our results support the role of CD23
activation and subsequent inflammatory response in arthritis.
Conclusion: CD23-blocking peptide (p30A) prevents the activation of monocytes/macrophages without cell toxicity. Thus,
targeting CD23 by antagonistic peptide decreases inflammatory markers and may have clinical value in the treatment of
human arthritis and allergic reactions involving CD23.
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Introduction
CD23 has been initially identified as low affinity receptor for
IgE on B cells, monocytes, follicular dendritic cells, Langerhan’s
cells, eosinophils, epithelial cells and platelets. CD23 is distin-
guished structurally from almost all other immunoglobulin
receptors as it belongs to the C-type (calcium dependent) lectin
superfamily [1]. In the membrane-bound form of CD23, three
lectin domains are spaced from the membrane by a triple a-helical
sequence susceptible to proteolysis, leading to the release of
various soluble fragments (sCD23) that have oligomeric state-
dependent activity [1]. The principal endogenous protease that
releases soluble CD23 has recently been identified as ADAM10
(disintegrin-metalloproteinase 10) [2]. CD23 has two isoforms with
two splice variants in their first seven (CD23a) or six (CD23b)
amino-acid residues in their N-terminal intracellular sequence.
The region that differs between the two splice forms is responsible
for their distinct signaling activities [3,4]. They are differentially
expressed: CD23a is expressed by antigen-activated B cells before
differentiation into antibody-secreting plasma cells, whereas
CD23b expression is induced by interleukin-4 (IL-4) on B cells
and a variety of inflammatory cells including epithelial cells.
CD23 plays a critical role during immune response including IgE-
synthesis, B- and T-cell differentiation, and the secretion of
inflammation mediators by various human cells [1]. Cross-linking
of surface CD23 promotes the generation of IL-1, IL-6, TNF-a,
H2O2 and nitric oxide synthase-2 (NOS2)-mediated NO through
NFkB- and AP-1-dependent mechanisms [5,6,7,8,9]. We and others
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4834have also demonstrated the role of CD23 during inflammation in
both Th1 and Th2 response [1,7,9]. In addition, soluble CD23
fragments mediate cell activation through the ligation of surface
CD11b/c on macrophages [10,11], or CD21 on lymphocytes [12].
CD23 role during inflammatory diseases was first suggested in
rheumatoid arthritis by the ability of anti-mouse CD23 antibody to
decrease cellular infiltration of the synovial sublining layer and the
destruction of cartilage, in mice with collagen-induced arthritis [13].
Accordingly, CD23-deficient mice had delayed onset and reduced
severity of collagen-induced arthritis [14]. Furthermore, CD23 is
expressed by peripheral blood monocytes from systemic juvenile
arthritis [15] or during adult arthritic crisis, while the physiopatho-
logic role of CD23 remains to be clarified in these diseases. Thus,
targeting CD23 could be of interest in the treatment of allergy and
inflammatory disorders. Hence, therapeutic CD23 monoclonal
antibody (McAb) was recently developed to block human CD23
during chronic lymphocytic leukemia [9].
In the present study, using small synthetic anti-CD23
heptapeptide, we selectively blocked human and rat CD23-
mediated cell activation, gene transcription and the generation
of various inflammatory factors as to identify new treatment for
inflammatory diseases.
Results
High affinity of peptide-CD23 interaction
Synthetic anti-CD23 heptapeptide p30A (FHENWPS) was
obtained using phage display technology as described (see under
Materials and methods and PCT Patent 098435). The addition of
p30A to normal human macrophages inhibits the binding of FITC-
conjugated anti-CD23 McAb (Figure 1A). In vitro, p30A was found
to block, on the one hand, the binding of IgE/anti-IgE-FITC to
human CD23
+ macrophages (Figure 1B), and on the other hand,
the detection of CD23 protein from human CD23
+ B cell line
extract (Figure 1C). We did not observed significant variations of
cell mortality and apoptosis in the presence of p30A compared to
cells incubated in medium alone (,5%). As p30A was generated
against soluble CD23, these data provide strong evidence that p30A
interacts with both soluble and surface CD23 forms with a higher
affinity than specific McAb or IgE-anti-IgE immune complexes.
p30A inhibits CD23-mediated cell signaling
Upon acquisition of CD23 surface expression, human cells may
be activated using its biological ligands (e.g. IgE/antigen) or cross-
linking with a specific anti-CD23 McAb [8,16]. McAbs (clones 135
and DM2, IgG1k) bind human CD23 with high affinity, promote
CD23 cross-linking, cell signaling and the transcription of
inducible nitric oxide synthase gene [17]. To confirm the ability
of p30A to inhibit CD23-mediated signaling in human macro-
phages, we pretreated cells with purified peptides prior to their
activation by McAb. Synthetic p30A reduced the levels of
inducible nitric oxide synthase (iNOS)-encoding mRNA
(Figure 2A). Nitrites, final metabolites of NO, were measured in
cell supernatants as a marker of iNOS activity. Generation of NO
from human macrophages was reversed by p30A in a dose-
dependent manner (Figure 2B) and similar to N(6)-(1-iminoethyl)-
L-lysine/2HCl (L-NIL)(Figure 2C), a specific inhibitor of iNOS
[18]. These effects were not observed with an irrelevant
heptapeptide, pCtl, used as control (SFNYNYA) (Figure 2B, 2C).
p30A decreases inflammatory response of normal and
arthritic patients’ monocyte/macrophage
CD23 signaling mediates cell activation and the generation of
various inflammatory mediators, involved in physiopathologic role
attributed to this molecule [1]. Specific inflammatory gene
transcription array (see Material and methods) was used to
analyze the effect of p30A on CD23-mediated activation of
macrophages from human healthy donors. Compared to resting
CD23
+ cells, cross-linking of CD23 induced a significant
expression of 38 new mRNAs (Table 1) encoding critical
inflammatory mediators, such as IL-1b, IL-6, IL-8, TNF-a,
lymphotoxin-a, TNF-R1 and MIF (Figure 3 and Table 1). These
findings underlined the critical role of CD23 during inflammatory
response of human macrophages. Heptapeptide p30A inhibits the
expression of most of the above mRNAs (24/38 were totally
suppressed) including IL-1b, IL-6, IL-8, TNF-a and TNF-R1
Figure 1. Specific blockade of CD23 reactivity by p30A. Flow
cytometry analysis showing the inhibition of (A) anti-CD23-FITC (20 mg/
ml) or (B) IgE (10 mg/ml)/anti-IgE-FITC (1 mg/ml) binding to CD23
+
human PBL-derived macrophages (red lines) or following their pre-
incubation with p30A peptides (10 mg/ml) (blue lines). (C) CD23
western blot was performed on total protein extract from a ` CD23
+ B-cell
line. The detection with CD23-McAb followed the pre-incubation of the
blot with or without p30A (10 mg/ml). Similar protein quantity (50 mg)
was used for each western blot condition.
doi:10.1371/journal.pone.0004834.g001
CD23-Blocking Peptides
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4834Figure 2. Inhibition of CD23-mediated activation of iNOS
pathway in human macrophages by p30A. Human CD23
+
monocyte-derived macrophages were incubated with cross-linking
CD23-McAb (20 mg/ml) alone or following 1 h pre-incubation with
10 mg/ml of various peptides. (A) Inducible NO-synthase expression
promoted by CD23-mediated activation is decreased in cells pre-
incubated with p30A. Expression of iNOS mRNA was compared to HPRT
mRNA levels. (B) Inhibition of NO generation from human activated
macrophages by synthetic peptides. Cell supernatants were collected
72 h following cell cultures and levels of nitrites were determined.
Dose-dependent reduction of nitrites was obtained with p30A
synthetic, whereas control peptides (pCtl) had no effect. Results are
expressed as mean of 3 distinct donor cell preparations (SEM,20%). (C)
Inducible NOS-mediated NO generation in human macrophages is
decreased following pre-incubation with p30A or L-NIL prior to CD23-
mediated activation. Results are expressed as mean6s.d. of 7 distinct
donor cell preparations.
doi:10.1371/journal.pone.0004834.g002
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PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4834(Figure 3 and Table I). In order to confirm these results, we further
quantified TNF-a, IL-6, IL-1b, IL-8 and IL-10 at protein levels
(Figure 4). Results showed that p30A significantly inhibited all
CD23-mediated activation of inflammatory mediators at protein
levels, supporting transcription results.
To substantiate above data, p30A was tested on CD23-
mediated activation of monocytes/macrophages from adult
arthritic patients during rheumatoid arthritis crisis. We supported
previous data showing that in those patients, high levels of CD23
+
monocytes/macrophages are detected in their synovial fluid [19]
and in peripheral blood [20], as regard to healthy individuals
(Figure 5A). Further, we purified peripheral and synovial fluid
monocytes/macrophages from various patients, and incubated
them with cross-linking anti-CD23 McAb. Nitric oxide, TNF-a
and IL-6 were quantified in culture supernatants as inflammatory
markers (Figure 5B). In contrast to healthy individuals, cells from
arthritic patients were shown to produce inflammatory factors
following CD23 activation. As predicted, addition of p30A to cells
prior to their activation reversed inflammatory mediators at the
same levels than control cell-supernatants (Figure 5B). These data
constitute the first evidence for direct role of CD23 in inducing
inflammatory response of cells from adult arthritic patients and
showed that p30A is effective in inhibiting CD23-mediated
activation of monocytes/macrophages from arthritic patients.
p30A prevents CD23-mediated activation of rat
macrophages in vitro and decreases arthritic signs and
bone destruction in vivo
To investigate the role of CD23 in the pathogenesis of arthritis
and the effects of blocking p30A in vivo, we used a rat model of
adjuvant-induced arthritis (AIA) which shows many clinical and
histopathological features close to human rheumatoid arthritis
[21]. In contrast to mice, these animals also express functional
CD23 on their macrophages [22] and constitute an appropriate
chronic model to study inflammatory role of both surface and
soluble CD23 [21,23]. In Figure 6A, we showed that p30A cross-
reacted with CD23 and was able to reverse the IgE/DNP
activation of rat macrophages ex-vivo as illustrated by significant
decrease in CD23-mediated induction of NO generation.
In vivo, we used the same protocol as for hydrocortisone: five
intracutaneous soluble doses, every two days after the onset of
arthritic symptoms. To assay disease prevention potential, we
injected p30A or control peptide to rats simultaneously to arthritis
induction with presumed causing agents, before the appearance of
any arthritic sign. As shown in Figure 6B, cumulative clinical
scores obtained following 50 days post-immunization indicate that
p30A significantly improved the clinical course of AIA rats as
compared to the control group of non-treated rats (Figure 6B,
p,0,0001). P30A was found to be more efficient than hydrocor-
tisone in decreasing arthritic scores (Figure 6B, 6C) and was
effective either after disease onset or for the prevention (Figure 6B,
p30A-d0) of induced-disease (p,0.0002).. Furthermore, this
beneficial effect was not found in animals treated with control
peptide. Histopathologic analysis 50 days after AIA induction
Figure 3. Inhibition of inflammatory gene transcription by
p30A in CD23-stimulated macrophages. Human CD23
+ monocyte-
derived macrophages were incubated with cross-linking CD23-McAb
(20 mg/ml) alone or following 1 h pre-incubation with 10 mg/ml of
p30A. Controls, activated cells with/without p30A pre-incubation are
figured. IL-1b, TNF-a and actin (ACT) mRNA location are indicated by
arrows. Shown is one representative experiment out of three.
doi:10.1371/journal.pone.0004834.g003
Figure 4. Inhibition of inflammatory mediator generation from
healthy human PBL-derived macrophages by p30A. Decreased
levels of TNF-a (A), IL-6 (B), IL-1b, IL-8 and IL-10 (C) were detected in
CD23-activated cells after incubation with p30A. No effect was
observed with control peptide (pCtl). Values are mean6s.d. of cells
from 5 (IL-6, TNF-a) or 2 (IL-1b, IL-8, IL-10) different donors.
doi:10.1371/journal.pone.0004834.g004
CD23-Blocking Peptides
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arthritic lesions: pannus formation and inflammation of the
synovium (Figure 6D), deformity of joint and bones (Figure 6D
asterix), bone remodeling and destruction (Figure 6D arrowhead),
bone neoformation (Figure 6D arrows) and cartilage destruction.
Moreover, no weight loss, neither intestinal bleeding was observed
during this period (data not shown) which indicate that p30A is an
effective and apparently safe therapy for AIA. To show the role of
p30A on macrophage-derived mediator release in vivo, we have
analysed the inflammatory markers of peritoneal cells from treated
and non-treated AIA rats. In this model, we observed an increased
IL-1 and TNFa release from peritoneal macrophages ex vivo
following AIA development (Figure 7). After various in vivo
treatments, peritoneal cells were isolated, promptly incubated
48 h in medium alone, and cell supernatants were analysed for the
levels IL-1b and TNFa. As shown in Figure 7, AIA-derived cells
expressed high IL-1b and TNFa levels compared to healthy rats.
Treatment with hydrocortisone moderately decreased IL-1b levels
while p30A, at both therapeutic and preventive pathways,
dramatically reduced both IL-1b and TNFa levels produced by
peritoneal cells ex vivo. Together, these results clearly demonstrate
in vivo inhibition of immune response by p30A in AIA rats.
Discussion
CD23 has emerged as a potential therapeutic target for a wide
range of inflammatory affections [1]. As original functional
approach, we here developed new specific CD23 heptapeptide
(p30A) able to target CD23-mediated activation of macrophages
and the subsequent secretion of pro-inflammatory mediators,
including TNF-a, IL-6 and NO. Based on in vitro studies we
showed that p30A addition to human macrophages greatly
diminished the transcription of genes encoding inflammatory
cytokines. This was also confirmed by significant reduction of
mediator levels in cell supernatants. It was also based on in vivo
studies that showed that administration of p30A to rat led to
amelioration of adjuvant-induced chronic arthritis. We also show
that p30A decreased IgE-mediated activation of both human and
rat CD23
+ macrophages. CD23-blocking peptide p30A prevents
the activation of monocytes/macrophages without cell toxicity.
CD23 has two isoforms CD23a and CD23b. On B lympho-
cytes, CD23a is associated with endocytosis of IgE coated particles,
whereas CD23b mediates phagocytosis of soluble IgE complexes
and the inflammatory response in rat and human cells [1,9].
CD23a is expressed (as by many other immune cells) by rat and
human epithelial cells [5,24] whereas in mice, CD23b is
restrictively expressed. The function of CD23 is further extended
by several physiological ligands. These comprise the complement
receptors CD21 (CR2) [12], aMb2-integrin (CD18/CD11b) and
aXb2-integrin (CD18/CD11c) [10]; the vitronectin receptor
(aVb3-integrin); and aVb5-integrin [25]. Data also indicate that
CD23 on epithelial cells plays a central role in transporting IgE
and allergen–IgE complexes across the epithelial-cell barrier [26].
Upregulation of the CD23 has been observed during various
allergic and inflammatory responses and is believed to play a role
in the bronchial mucosa through the enhancement of antigen
uptake and presentation [9,27]. CD23 cross-linking mediates the
activation of human macrophage inflammatory reaction in the
presence of IgE. We have previously demonstrated that CD23-
mediated IgE-antigen-induced activation of inducible nitric oxide
synthase, IL-1 and TNF-a in various human cells including
macrophages [17], eosinophils [7] and epidermal epithelial cells
[5,28]. Multiple signaling pathways, including p38 mitogen
activated protein kinase (MAPK), JNK, and Erk pathways may
be involved in the regulation of pro-inflammatory mediators
following this CD23 activation [9]. CD23 dramatically enhanced
antigen complex presentation compared to unfocused or IgG-
bound antigen in animal studies. This suggests that CD23 may
amplify immune response to autoantigens during arthritis.
Monocytes and eosinophils are among the different inflamma-
tion effector cells that are drawn to sites of inflammation, where
IL-4, IL-13, IFN-c and GM-CSF stimulate the expression of
CD23 by these cells [7,9]. This in turn, arms the cells for useful
functions, such as clearance of antigen, killing and phagocytosis of
pathogens (for example, helminthes) [17] and tumor cells that bear
‘foreign’ antigens [29]. The upregulation of CD23 also leads to the
Figure 5. p30A inhibits the production of CD23-dependent
inflammatory mediator release in cells from rheumatoid
arthritis (RA) patients. (A) PBL and synovial monocytes/macrophag-
es from RA patients were labeled with anti-CD23-FITC or isotype-
matched (Iso) McAb and compared to healthy PBL. Representative
fluorescence intensity data obtained from one case, out of 11 distinct
patients or healthy individuals. (B) Inhibition of inflammatory mediator
release from RA patients derived monocytes/macrophages. PBL
monocytes or macrophages collected from synovial liquid were
activated through CD23 after 1 h pre-incubation with/without p30A
or pCtl. Cell supernatants were collected 72 h later and nitrites, TNF-a
and IL-6 were quantified. Values are expressed as mean6s.e.m from 7
patients’ cells.
doi:10.1371/journal.pone.0004834.g005
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and thereby initiate the production of tumor-necrosis factor and
other pro-inflammatory cytokines [30]. In carrying out their
functions, monocytes and eosinophils inevitably also inflict some
damage on bystander cells in the tissue. This side effect ultimately
contributes to tissue remodeling and exacerbates the symptoms of
various inflammatory diseases [7].
Authors reported overexpression of membrane bound and
sCD23 during acute juvenile or adult arthritis, with a clear pro-
inflammatory property in this form [15]. In the present study, we
report similar observations in peripheral and synovial liquid
monocytes/macrophages from adult arthritic patients (Figure 5).
We also showed the capacity of these CD23
+ cells to directly
undergo CD23 activation, in contrast to cells from healthy
individuals. These results reinforced the notion of the systemic
involvement via the peripheral monocytes in RA diseases and
pointed out the role of CD23 as disease-related marker during
arthritic crisis. Steroids have a clear inhibitory effect on CD23
expression and cell signaling, which may account for their anti-
inflammatory effects [31]. Moreover, CD23-mediated signaling
and subsequent nitric oxide and TNF-a production by human
macrophages and epithelial cells were also been shown to be
Figure 6. Inhibition of in vitro and in vivo inflammatory responses in rats by p30A peptide. (A) Rat peritoneal macrophages were activated
via CD23 antigens with/without p30A, L-NIL or pCtl. Cell supernatants were collected 48 h later and nitrite levels were quantified. Values are
mean6s.d. of cells from 3 different rats. (B) Cumulative clinical score/rat obtained following 50 days post-immunization in all groups. AIA rats were
treated either after or before (d0) the onset of symptoms. Treatment consisted of p30A, hydrocortisone (HC, 30 mg/rat)) or pCtl (100 mg/rat). Shown
are means of cumulative score/rat6s.d. from 5 (HC) or 8 rats (other conditions). (C) Evolution of arthritis severity scores of adjuvant-induced arthritis
(AIA) in rats treated with intracutaneous p30A or pCtl (100 mg/rat) or hydrocortisone (after the onset of clinical signs as illustrated by arrows (means
from 8 rats, s.e.m.,20%). (D) Histopathologic analysis confirm p30A ability to decrease all components of AIA lesions: pannus formation and
inflammation of the synovium (P), deformity of joint and bones (asterix), bone remodeling and destruction (arrowhead), bone neoformation (arrows)
and cartilage destruction.
doi:10.1371/journal.pone.0004834.g006
Figure 7. Decreased inflammatory markers of peritoneal
macrophages following in vivo treatment with p30A peptide.
AIA rats were treated either after (AIA+p30A) or before (p30A+AIA) the
onset of symptoms. Treatment consisted of p30A (10 mg/rat) or
hydrocortisone (HC, 30 mg/rat). Rat peritoneal macrophages were
collected following 50 days post-immunization, washed and re-
incubated in culture medium alone. Cell supernatants were collected
48 h later and cytokine levels were quantified. Macrophages from
healthy rats were also incubated in similar conditions. Values are
mean6s.d. of cells from 4 different rats.
doi:10.1371/journal.pone.0004834.g007
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1 inhibitor cytokine.
CD23 was also directly triggered by specific antibodies as
therapeutic approach. This was firstly showed in an experimental
arthritic mice model where an anti-CD23 administration de-
creased all pathological signs and corroborated studies showing a
reduced arthritic signs in CD23-deficient animals [13,14].
Primate/human CD23-McAb, lumiliximab, developed for the
treatment of chronic lymphocytic leukemia, has also been shown
to a promising therapy in Phase I of clinical trials for asthma [9].
Similarly, p30A specifically bound human and rat CD23, blocked
CD23-mediated cell activation and decreased CD23-mediated
activation of peripheral and synovial monocytes/macrophages
from patients during arthritic crisis. To confirm these results, we
used rat model of chronic arthritis because, as human cells, rat
macrophages are known to fully express CD23b isoform in vivo
[22] in opposition with mouse model. Clearly, p30A decreased
arthritic signs in rats in a dose-dependent manner. Furthermore,
administration of p30A prior to disease induction prevented the
development of severe clinical signs in rats. These data clearly
support a role for CD23 in the pathogenesis of arthritis and the
interest of the use of small peptides as therapeutic tools [33]. Data
in rat model of chronic arthritis show a clear dose-dependent long
term effect (.one month), indirectly supporting the stability of
p30A in vivo. P30A had several advantages: small size, easy
synthesis and the absence of side agonistic effect compared to the
pro-apoptotic activity of anti-CD23 antibodies [34]. Even if
further investigations are needed to confirm these results in
human, p30A should be considered as a potent candidate
molecule in the treatment of RA.
Materials and Methods
Anti-CD23 peptides
p30A peptide used in this study is a synthetic linear
heptapeptide (FHENWPS) obtained by panning a phage displayed
peptide M13 library (Ph.D 7, New England BioLabs, Ipswich,
MA, USA) on purified sCD23 protein (soluble 25 kDa, kind gift
from E. Kilcchher, Novartis, Basel) [35] as detailed elsewhere
(PCT Patent 098435). As control (pCtl), we have used synthetic
heptapeptide with unrelated sequence (SFNYNYA).
Human Cells
Peripheral blood samples pre-tested for the absence of HIV or
hepatitis virus infections were obtained from healthy volunteers
(EFS Aquitaine, Bordeaux Blood Bank). We also collected paired
peripheral blood and synovial fluid from seven patients, who
fulfilled the American College of Rheumatology criteria for RA,
during arthritic crisis. Written informed consent was obtained
from all the patients. This study was carried out in compliance
with the Helsinski Declaration and was approved by the National
Ethical Authorities. All seven patients had previously received
conventional therapy but none has been given TNF blocker or any
other biologic treatment for their condition. Whole leukocytes
were then suspended in McCoy 5A modified culture medium
supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin,
25 mM HEPES, 0.1 mM 2-mercaptoethanol, 2 mM sodium
pyruvate, 0.2 mM L-cysteine, 5 mg/ml polymyxin B and 10%
fetal calf serum (FCS) (all from Gibco-Europe, Paisley, Scotland).
All the above culture medium, chemicals, and FCS were
endotoxin-free and tested for the absence of direct activation
effects on human monocytes (CD23 expression and TNF-a
production as activation markers). Peripheral blood-derived
mononuclear leukocytes (PBL) were obtained by Ficoll gradient
separation and monocytes were subsequently separated from other
leukocytes by adherence to FCS-coated culture flasks or CD14
beads (Miltenyi Biotec, Paris, France). Synovial fluid was diluted
with culture medium and adherent cells obtained following
incubation into FCS-coated culture flasks. Following these
procedures, .95% of cells expressed CD14 antigen and displayed
cytochemical characteristics of monocytes/macrophages [17].
Human cell activation
Monocytes or macrophages were activated through CD23
pathway: while monocytes/macrophages from RA patients
express CD23, monocytes from healthy donors must be pre-
activated to express surface CD23 as described [17]. This pre-
activation was obtained by incubation of healthy monocytes with
recombinant human IL-4 (20 ng/ml) during 48 h at 37uC; After
washing, all cell populations were tested by flow cytometry for
their surface CD23 expression (.80% CD23
+) and then incubated
in the presence of cross-linking CD23-MAb (clones 135 or DM2,
IgG1k, 20 mg/ml) during 48–72 h, or IgE and anti-IgE as
described [5,17]. When indicated, peptides were added to the
cells 2 h prior to their activation. Cells supernatants were then
analyzed for their nitric oxide content (see below) and for the
presence of cytokines: levels of TNF-a and IL-6 were determined
in duplicates for each sample by a specific ELISA (R&D, Paris,
France) while levels of IL-1b, IL-8 and IL-10 was determined
using FlowCytomix Human Th1/Th2 Kit as recommended
(Bender Medsystems, Vienna, Austria).
Western blot
Total cellular proteins were isolated from CD23
+, ADAM B-cell
line in cell lysis buffer (10 mM Tris pH 8.0, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 0.05% SDS, 10 mM Sodium Fluoride,
1 mM Sodium Orthovanadate, 5 mM Molibdic Acid) and a
mixture of protease inhibitors (all from Sigma Aldrich, Saint
Quentin Fallavier, France). Protein concentration was determined
using the Bradford assay (Bio Rad, Hemel Hempstead, UK).
Protein samples (50 mg total protein) were subjected to SDS-
PAGE using a 12% resolving gel. The separated proteins were
electro-transferred to PDVF membrane (Millipore, Bedford, UK)
for 1 h to 15 V. The membrane was blocked 1 h at room
temperature in 5% BSA in TBS-tween (TBS-T) and incubated
with different concentrations of p30A (10, 20 and 40 mg/ml) in
TBS-T for 2 h. The membranes were then incubated with either
0.5 mg/ml mouse anti-human CD23 or 0.5 mg/ml mouse anti-
human Bcl2 (both from Dako Cytomation, Glostrup, Denmark)
overnight at room temperature. Membranes were washed 18 h
later in TBS-T and re-incubated with goat anti-mouse IgG
peroxydase-conjugated (1/10000, Vector, Burlingame, USA) for
1 h at room temperature. The membranes were washed in TBS-T
and visualized with an enhanced chemiluminescence system
(Perkin Elmer, Boston, USA). Immunoreactive bands (CD23 and
Bcl2) were detected using the FluorChem 8800 (Alpha Innotech,
San Leandro, USA) and semi-quantified by densitometry using
AlphaEase FC (Alpha Innotech).
RNA preparations and transcriptomic arrays
Following cultures, total RNA was extracted using RNeasy kit
(Qiagen, Hilden, Germany). Synthesis, purification and hybrid-
ization of biotin-labeled cRNA (6 mg) to custom array membranes
were performed according to manufacturer’s recommendations
(Oligo GEArrayH Human Inflammatory Cytokines and Receptors
Microarray, ref OHS-011, Superarray Bioscience, Frederick,
MD). After local background subtraction, average signal intensity
from duplicate spots was compared to values obtained for
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capture software (Alpha-Innotec, San Leandro, CA). For each
gene, modulation was defined as the relative expression value for
stimulated vs. control sample.
Analysis of NO pathway
Culture supernatants (72 h) were assayed for the stable end-
product of NO, NO2
2 using the Griess reaction modified as detailed
elsewhere [36]. Inhibitory analog of L-arginine, L-NIL (N(6)-(1-
iminoethyl)-L-lysine/2HCl, Coger SA, Paris, France) was used to
inhibit iNOS-mediated NO generation. This method gave a
sensitivity limit of 0.2 mMi fl o wN O 2
2 medium (DMEM) was used.
Total RNA was isolated as above from peritoneal macrophages.
Reverse transcription-PCR was performed with an automatic
thermal cycler (iCycler, Biorad) using the following specific primers:
iNOS mRNA sense (59-ATGCCAGATGGCAGCATCAGA-39,
exon 8) and iNOS mRNA antisense (59-ACTTCCTCCAG-
GATGTTGTA-39,e x o n1 1 ) .H y p o x a n t h i n ep hosphoribosyltransfer-
ase (HPRT) mRNA sense (59-TATGGACAGGACTGAAC-
GTCTTGC-39) and HPRT mRNA antisense (59-GACACAAA-
CATGATTCAAATCCCTGA- 39) primers were used as controls.
The iNOS messenger is represented by a 371-bp band, whereas a
496-bp band indicates the HPRT messenger [17].
Experimental arthritis and rats
All animal procedures were performed in strict accordance with
the guidelines issued by the European Economic Community
‘‘86/609’’. Female Lewis rats (Janvier, Le Genest St Isle, France)
were housed under standard laboratory conditions with free access
to food and water. The temperature was kept at 2262uC and a
12 hour light/dark schedule was maintained.
For macrophage collection, animals were anaesthetized with
ether and the peritoneal cavity was washed with 10 ml of cold
PBS, pH 7.4. After centrifugation at 1200 g for 10 min at 4uC,
cells were collected, counted and adjusted to 2610
5 cells per ml
with RPMI 1640 culture medium supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin and 10% heat-inactivated
FCS. To activate the production of various inflammatory
mediators from rat peritoneal macrophages, cells were incubated
with lipopolysaccharide (LPS, 1–5 mg/ml; Sigma), or IgE/DNP as
described [19]. Peptides were added one hour prior to cell
activation. Cells or their culture supernatants were then tested for
the presence of various inflammatory mediators.
Adjuvant arthritis was induced in six week-old animals by
subcutaneous injection at the base of the tail of 300 ml containing
1.8 mg of inactivated Mycobacterium butyricum (Difco Laboratories,
Detroit, MI) diluted in emulsion of 8 ml Vaseline, 1 ml
polysorbate 80, and 1 ml PBS (Phosphate Buffer Saline, Eurobio).
Rats were boosted one week later following the same procedure.
Observation was conducted for up to 50 days following
immunization for clinical signs of arthritis. Rats were divided in
different groups of 8 rats. Groups were treated with five injections
(every 2 days) of either p30A (10, 50 or 100 mg in a PBS solution),
pCtl, hydrocortisone (Sigma Aldrich) or PBS solution. Injections
were initiated two days after the appearance of first arthritic
symptoms (therapeutic) or on the first day of immunization
(preventive). Evaluation of AIA severity was performed by two
independent observers who where not aware of the study protocol.
The severity of AIA in each paw was quantified daily using an
ordinal clinical score measurement from 0 to 4 as follows: no signs
of inflammation (=0); swelling alone (.2 fold paw diameter) (=1)
or swelling/immobility (=2) of one paw; swelling (=3) or
swelling/immobility (=4) of two paws. Weight evolution of rats
was measured daily. Rats were sacrificed 50 days after AIA
induction. Peritoneal macrophages were collected and incubated
in culture medium alone for 48 h. Quantification of TNF-a and
IL-1b in rat cell supernatants was performed using appropriate
ELISA kits and according to manufacturer’s recommendations
(Biosource, Montrouge, France).
For histological analysis, the forelimbs were fixed in 4%
buffered formalin, decalcified by electrophoresis in decalcifying
buffer (Bayer Diagnostic, Puteau, France) for 3 h and embedded
in paraffin. Thick sections of five mm were stained with
hematoxylin, eosin, safran (HES) using routine protocols.
Statistical analysis
Comparisons were assessed using Fischer’s exact test for
proportions and Mann-Whitney-U test for quantitative values.
P,0.05 was considered to be significant. Results were analyzed
and compared using the Student t-test for paired data.
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